Comparative Pharmacology
Head-to-head clinical analysis: KEVEYIS versus TRUSOPT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KEVEYIS versus TRUSOPT.
KEVEYIS vs TRUSOPT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Keveyis (dichlorphenamide) is a carbonic anhydrase inhibitor. It reduces the frequency of attacks in primary hyperkalemic periodic paralysis by decreasing intracellular pH, which stabilizes muscle cell membranes and reduces potassium efflux from muscle cells.
Carbonic anhydrase inhibitor; decreases aqueous humor secretion by inhibiting carbonic anhydrase in the ciliary processes of the eye.
50 mg orally twice daily with food; may increase to 100 mg twice daily after 2 weeks if needed.
One drop of 2% solution in affected eye(s) twice daily, approximately 12 hours apart.
None Documented
None Documented
Terminal elimination half-life: 15–20 hours following a single oral dose; at steady state, half-life 42–80 hours (mean ~60 h) due to dose-dependent kinetics.
Terminal elimination half-life of dorzolamide in whole blood is approximately 4 months due to tight binding to carbonic anhydrase in red blood cells; however, the drug's clinical effect on intraocular pressure has a half-life of about 24 hours.
Primarily renal: unchanged drug accounts for ~82% of dose in urine; fecal excretion <5%; minor hepatic metabolism.
Renal excretion as unchanged drug: approximately 70% of a topically applied dose is excreted renally; the remainder is eliminated via biliary/fecal routes (30%). Following oral administration, renal excretion accounts for about 65-70%.
Category C
Category C
Carbonic Anhydrase Inhibitor
Carbonic Anhydrase Inhibitor